We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 95

Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?

  • Bryan Cave LLP
  • -
  • European Union, France, Germany, Italy, United Kingdom
  • -
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the

Pre-expiry offers to supply after patent term expiry

  • Taylor Wessing
  • -
  • Austria, Germany, United Kingdom
  • -
  • August 6 2013

Patent infringement by pre-expiry offer to supply a product after the patent has expired is an area of acute difficulty in Austria. In Austria, two

Risk-sharing and other new business models for pharmaceutical companies in Germany

  • Hogan Lovells
  • -
  • Germany
  • -
  • August 31 2008

The German Federal Law to Increase Competition among Statutory Health Insurance Funds from April 1, 2007 has ushered in major changes regarding the way pharmaceutical companies do business in Germany

Health Canada says BPA in canned foods poses no risk; Germany advises manufacturers to find alternatives

  • Shook Hardy & Bacon LLP
  • -
  • Canada, Germany, USA
  • -
  • June 11 2010

Health Canada's Bureau of Chemical Safety has released a survey of bisphenol A (BPA) in canned foods that finds low rates of exposure and no risk to public health

Yet another health reform and seizure of retiring doctors' practices

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • February 19 2014

The new German government intends to increase competition in the healthcare sector by varying insurance premiums

Germany seeks stricter nanomaterial reporting rules under REACH

  • Shook Hardy & Bacon LLP
  • -
  • European Union, Germany
  • -
  • May 10 2013

German safety regulators have apparently sought a major nanotechnologyrelated revision of the European Union's Registration, Evaluation

An end to free pricing in the German pharmaceuticals market

  • McDermott Will & Emery
  • -
  • Germany
  • -
  • November 22 2010

Germany has long been the only country in Europe that allows pharmaceutical producers to determine freely their prices for new, supposedly innovative products

Amendments to German Drug Advertising Act

  • Baker & McKenzie
  • -
  • Germany
  • -
  • March 26 2013

Amendments have been made to the German Drug Advertising Act (HeilmittelwerbegesetzHWG) (Act) by the so-called "Second Act Amending Drug Law and

Award procedures in the field of emergency services

  • Schoenherr
  • -
  • Austria, European Union, Germany
  • -
  • February 7 2011

According to the European Court of Justice (ECJ), emergency and rescue transport services are not connected with the exercise of official authority and therefore not exempt from applicability of the Public Procurement Directive (200418EC

It might take three to Bolar

  • De Brauw Blackstone Westbroek
  • -
  • Germany
  • -
  • February 10 2014

The Düsseldorf Court of Appeal recently challenged established opinion that a third-party's supply of ingredients to a generic pharmaceutical